NCT04607421 2025-08-14A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal CancerPfizerPhase 3 Active not recruiting831 enrolled 2 FDA
NCT02675946 2022-01-26CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596)Curegenix Inc.Phase 1 Unknown72 enrolled